|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Aclasta inj[骨力強 注射劑] information |
|
|
|
製造商 |
Novartis |
|
代理/經銷商 |
Novartis |
|
成份 |
Zoledronic acid |
|
適應症 |
Treatment of Paget's disease of bone & postmenopausal osteoporosis . |
|
用量 |
Paget's bone disease 5 mg as a single 15-min IV infusion with recommended daily allowance of supplemental Ca & vit D.during the initial 2 weeks following administration. Postmenopausal osteoporosis 5 mg once a year as a single 15-min IV infusion. Supplement with Ca 1200 mg & vit D 400-800 iu daily. |
|
過量 |
View Aclasta[骨力強] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Hypocalcemia. Pregnancy & lactation. Severe renal impairment. |
|
注意事項 |
Patients must be appropriately hydrated prior to administration. Pre-existing hypocalcemia must be treated by adequate intake of Ca & vit D before initiating therapy. Dental exam with appropriate preventive dentistry should be considered prior to treatment in patients with concomitant risk factors (eg. cancer, chemotherapy, corticosteroids, poor oral hygiene). Avoid invasive dental procedures during treatment. |
|
不良反應 |
Influenza, hypocalcemia, headache, lethargy, dyspnea, diarrhea, nausea, dyspepsia, bone pain, arthralgia, myalgia, flu-like symptoms, pyrexia, rigors, fatigue, pain, asthenia. Local site reactions. Osteonecrosis of the jaw.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Drugs that can significantly impact renal function, eg aminoglycosides, diuretics.
View more drug interactions with Aclasta[骨力強] |
|
儲存 |
View Aclasta[骨力強] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Aclasta[骨力強] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Aclasta[骨力強] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Aclasta 注射劑 |
|
Aclasta 5 mg/100 mL x 100 mL |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Novartis |
|
 |
|
|
|
